Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. (Full text)

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show (...) -mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).Copyright © 2020 Massachusetts Medical Society.

2020 NEJM PubMed abstract

2. t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes

) is for continuous subcutaneous insulin delivery to manage blood glucose levels in people with type 1 diabetes. The device is up to 38% smaller than other insulin pumps and has a watertight aluminium case and shatter-resistant colour touch screen interface. The flat insulin cartridge accommodates up to 300 units of insulin. Rapid-acting insulin is delivered from the device through thin flexible tubing to a cannula placed under the skin. The infusion site is changed every 2 days to 3 days. The t:slim X2 pump can (...) litre. Control- IQ also uses activity and sleep settings. The device has a rechargeable battery, USB ports and the software can be updated remotely using t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 16a personal computer during the 4-year warranty of the pump. Patients can also upload their device data using the Diasend

2020 National Institute for Health and Clinical Excellence - Advice

3. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) Lancet Diabetes Endocrinol Actions . 2020 Sep 21;S2213-8587(20)30313-2. doi: 10.1016/S2213-8587(20)30313-2. Online ahead of print. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials , , , , , , , , Affiliations Expand Affiliations 1 KfH Kidney Center, Munich, Germany; Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany. Electronic address: johannes.mann

2020 EvidenceUpdates

4. Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Control: A Randomized Controlled Trial

. Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Glycemic Control: A Randomized Controlled Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. 2 Centre for Biostatistics, Division of Health Sciences, University of Otago, Dunedin, New Zealand. 3 Department of Paediatrics and Child Health, University of Otago, Wellington, Wellington, New (...) Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Control: A Randomized Controlled Trial Effect of 6 Months of Flash Glucose Monitoring in Youth With Type 1 Diabetes and High-Risk Glycemic Control: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19

2020 EvidenceUpdates

5. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index >/=27 kg/m(2) (Full text)

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index >/=27 kg/m(2) Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m 2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) ahead of print. Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m 2 , , , , , , , , , Affiliations Expand Affiliations 1 Clinical and Experimental Endocrinology, UZ Gasthuisberg, University of Leuven, Leuven, Belgium. 2 State University of New York at Buffalo, Williamsville, New York, USA. 3 Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich, University of Tübingen, Tübingen

2020 EvidenceUpdates PubMed abstract

6. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. (Abstract)

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes.We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial to investigate the efficacy and safety (...) of once-weekly insulin icodec as compared with once-daily insulin glargine U100 in patients who had not previously received long-term insulin treatment and whose type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking metformin with or without a dipeptidyl peptidase 4 inhibitor. The primary end point was the change in glycated hemoglobin level from baseline to week 26. Safety end points, including episodes of hypoglycemia and insulin-related adverse events

2020 NEJM

7. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. (Abstract)

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors could increase the risk for diabetic ketoacidosis (DKA).To assess whether SGLT-2 inhibitors, compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, are associated with an increased risk for DKA in patients with type 2 diabetes.Population-based cohort study; prevalent new-user design between 2013 and 2018. (ClinicalTrials.gov (...) : NCT04017221).Electronic health care databases from 7 Canadian provinces and the United Kingdom.208 757 new users of SGLT-2 inhibitors were matched by using time-conditional propensity scores to 208 757 recipients of DPP-4 inhibitors.Cox proportional hazards models estimated site-specific hazard ratios (HRs) with 95% CIs of DKA comparing receipt of SGLT-2 inhibitors with receipt of DPP-4 inhibitors, which were pooled by using random-effects models. Secondary analyses were stratified by molecule, age, sex

2020 Annals of Internal Medicine

8. Semaglutide (Rybelsus) - For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise

Semaglutide (Rybelsus) - For the treatment of adults with insufficiently controlled type 2 diabetes (T2D) to improve glycaemic control as an adjunct to diet and exercise 1 Published 7 September 2020 Product update SMC2287 semaglutide 3mg, 7mg and 14mg tablets (Rybelsus®) Novo Nordisk 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following assessment under the abbreviated process semaglutide (Rybelsus®) is accepted for restricted use within NHSScotland. Indication under review: for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise ? As monotherapy when metformin is considered inappropriate due to intolerance or contraindications ? In combination with other

2020 Scottish Medicines Consortium

9. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison (Full text)

Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison - PubMed This site needs JavaScript to work properly. Please enable (...) options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Jul 6. doi: 10.1111/dom.14136. Online ahead of print. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison , , , , , , , , Affiliations Expand Affiliations 1 Translational and Clinical Research Institute, Newcastle University, Newcastle upon

2020 EvidenceUpdates PubMed abstract

10. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study

Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 28;dc200736. doi: 10.2337/dc20-0736. Online ahead of print. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA 1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study , , , , , , , Affiliations Expand Affiliations 1 Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K. hood.thabit@mft.nhs.uk. 2 Division of Diabetes (...) Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study Hood Thabit et al. Diabetes Care . 2020 . Show details Display options Display options Format Diabetes Care Actions . 2020 Jul 28;dc200736. doi: 10.2337/dc20-0736. Online ahead of print. Authors , , , , , , , Affiliations 1 Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K. hood.thabit@mft.nhs.uk. 2 Division of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health

2020 EvidenceUpdates

11. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial - PubMed This site needs JavaScript to work properly (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Jul 21;dc192316. doi: 10.2337/dc19-2316. Online ahead of print. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial , , , , , , , , Affiliations Expand Affiliations 1 Dallas Diabetes Research Center at Medical City

2020 EvidenceUpdates

12. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) (Full text)

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) - PubMed This site needs JavaScript (...) Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Sep;43(9):2025-2033. doi: 10.2337/dc20-0408. Epub 2020 Jul 13. Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA) , , , , , , , , , , Affiliations Expand Affiliations 1 Steno Diabetes Center

2020 EvidenceUpdates PubMed abstract

13. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Aug 14;dc201104. doi: 10.2337/dc20-1104. Online ahead of print. Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

14. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2

Metab Actions . 2020 Jul 3. doi: 10.1111/dom.14127. Online ahead of print. Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 , , , , , , , Affiliations Expand Affiliations 1 Endocrine and Metabolic Consultants, Rockville, Maryland, USA. 2 Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy. 3 Diabetes Centers of America-Dallas (...) Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

15. Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis

Evidenced-Based Medicine Reviews, CINAHL, Embase, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, PROSPERO, PsycInfo, PubMed, and Web of Science until 24 April 2019. Study selection: We included randomized controlled trials ≥2 weeks' duration comparing technologies for management of type 1 diabetes in adults (≥18 years of age), excluding pregnant women. Data extraction: Data were extracted using a predefined template. Outcomes were percent time with sensor glucose levels 3.9-10.0 mmol/L (70 (...) Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest

2020 EvidenceUpdates

16. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. (Abstract)

Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. The American Diabetes Association (ADA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of diabetes.To develop the 2020 Standards, the ADA Professional (...) Practice Committee, comprising physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, pharmacists, and public health experts, continuously searched MEDLINE (English language only) from 15 October 2018 through August-September 2019 for pertinent studies, including high-quality trials that addressed pharmacologic management of type 2 diabetes. The committee selected and reviewed the studies, developed the recommendations, and solicited feedback from

2020 Annals of Internal Medicine

17. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. (Abstract)

A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.In a 16-week, multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of either a closed-loop system of insulin delivery (closed-loop group) or a sensor-augmented (...) that the system was in the closed-loop mode was 93% (interquartile range, 91 to 95). No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either group.In this 16-week trial involving children with type 1 diabetes, the glucose level was in the target range for a greater percentage of time with the use of a closed-loop system than with the use of a sensor-augmented insulin pump. (Funded by Tandem Diabetes Care and the National Institute of Diabetes and Digestive and Kidney Diseases

2020 NEJM

18. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. (Abstract)

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Several pharmacologic options for type 2 diabetes are available.To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes.Several databases from inception through 18 December 2019 and ClinicalTrials.gov on 10 April 2020.English-language randomized trials that had at least 24 weeks of intervention and assessed the effects of glucose-lowering drugs (...) exenatide, and dapagliflozin reduced all-cause mortality. Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death. Odds of stroke were lower with subcutaneous semaglutide and dulaglutide. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease. Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy and amputation, respectively.Inconsistent definitions of cardiovascular risk and low-level confidence

2020 Annals of Internal Medicine

19. Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes EXPERT CONSENSUS DECISION PATHWAY 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes A Report of the American College of Cardiology Solution Set Oversight Committee Endorsed by the American Diabetes Association Writing Committee Sandeep R. Das, MD, MPH, FACC, Co-Chair Brendan M. Everett, MD, MPH, FACC, Co-Chair Kim K. Birtcher, PHARMD, MS (...) .2020Expertconsensusdecisionpathwayonnoveltherapiesforcardiovascularrisk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020;XX:XXX–XX. Copies: This document is available on the World Wide Web site of the American College of Cardiology (www.acc.org). For copies of this document, please contact Elsevier Inc. Reprint Department via fax (212) 633-3820 or e-mail (reprints@elsevier.com). Permissions: Multiple copies, modi?cation, alteration, enhancement, and/or distribution

2020 American College of Cardiology

20. Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial

Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Gen Intern Med Actions . 2020 Jul 22. doi: 10.1007/s11606-020-06011-w. Online ahead of print. Mobile-Enhanced Peer Support for African Americans with Type 2 Diabetes: a Randomized Controlled Trial , , , , Affiliations Expand

2020 EvidenceUpdates